Tyme Technologies (NASDAQ:TYME) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.
Several other brokerages have also issued reports on TYME. Canaccord Genuity assumed coverage on Tyme Technologies in a report on Wednesday, January 3rd. They set a “buy” rating on the stock. Evercore ISI assumed coverage on Tyme Technologies in a report on Friday, November 17th. They set an “outperform” rating and a $7.00 price objective on the stock. Finally, HC Wainwright assumed coverage on Tyme Technologies in a report on Friday, December 15th. They set a “buy” rating and a $8.00 price objective on the stock.
Shares of Tyme Technologies (NASDAQ:TYME) traded down $0.15 during mid-day trading on Friday, hitting $5.01. The company’s stock had a trading volume of 47,198 shares, compared to its average volume of 215,955. The stock has a market capitalization of $434.49, a price-to-earnings ratio of -31.31 and a beta of -42.35. Tyme Technologies has a 12 month low of $2.14 and a 12 month high of $9.50.
In related news, COO Michael Demurjian sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $3.34, for a total transaction of $167,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
A hedge fund recently bought a new stake in Tyme Technologies stock. Franklin Street Advisors Inc. NC acquired a new stake in Tyme Technologies, Inc. (NASDAQ:TYME) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 31,000 shares of the company’s stock, valued at approximately $198,000. Hedge funds and other institutional investors own 2.45% of the company’s stock.
Tyme Technologies Company Profile
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.